Cytosol Laboratories Inc., a Braintree maker of small volume anticoagulants, has been acquired by Biomet Inc., a manufacturer of musculoskeletal medical products, for an undisclosed amount.
Founded in 1968, Cytosol develops anticoagulants and other products to aid in the processing of blood components. The company has three products that have received New Drug Application approvals from the U.S. Food and Drug Administration: TriCitrasol, noClot-50 and Rejuvesol.
According to officials at Indiana-based Biomet, the technology acquired with Cytosol will work well with Biomet’s existing GPS III Platelet Separation System and BioCue Platelet Concentration System. While the release stated that Biomet was buying “substantially all of the assets” of Cytosol, it did not specify what it was not acquiring. Without stating any details of how many employees would be retained, Biomet Biologics president Stuart Kleopfer said that he welcomed the team from Cytosol.
When Cytosol was formed, it was initially tasked with creating specialty blood processing products for Massachusetts General Hospital, according to its wesbite.